Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2024; 30(25): 3132-3139
Published online Jul 7, 2024. doi: 10.3748/wjg.v30.i25.3132
Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease
Di Wang, Bing-Yan Zhou, Lei Xiang, Xu-Yong Chen, Jie-Xiong Feng
Di Wang, Bing-Yan Zhou, Lei Xiang, Xu-Yong Chen, Jie-Xiong Feng, Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Co-first authors: Di Wang and Bing-Yan Zhou.
Author contributions: Wang D drafted the manuscript; Zhou BY and Xiang L reviewed the literature; Feng JX conceived the idea and coordinated the manuscript; Chen XY and Feng JX approved the final version of the article.
Supported by National Natural Science Foundation of China, No. 81873541.
Conflict-of-interest statement: There is no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie-Xiong Feng, MD, PhD, Chief Doctor, Professor, Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Ave, Wuhan 430030, Hubei Province, China. 2002tj0515@hust.edu.cn
Received: March 6, 2024
Revised: May 7, 2024
Accepted: June 13, 2024
Published online: July 7, 2024
Processing time: 117 Days and 4.1 Hours
Core Tip

Core Tip: This editorial discusses the article by Chen et al regarding the association between high-normal alanine aminotransferase (ALT) levels and the onset of metabolic dysfunction-associated fatty liver disease (MAFLD) in China. As an indicator of liver function, ALT could be considered a marker of the presence of MAFLD. Therefore, tracking cumulative ALT levels could enhance early MAFLD detection. Improved detection through ALT tracking could enable timely intervention, thereby enhancing overall health outcomes for individuals at risk of developing this increasingly common liver condition.